Neurocrine Biosciences Inc.

NBIX | NASDAQ

Price Alert Chart Builder DCF Calculator

$142.49

-$1.47 (-1.02%)

Sep 22, 2026, 2:39 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $14.48B

Enterprise Value $14.49B

Beta 0.38

Average Volume 1.25M

Shares Outstanding (Diluted) 104.2M

Shares Change YoY 3.17%

Institutional Ownership 99.67%

Exchange NASDAQ

ISIN US64125C1099

Price Performance

Price Change 1M -6.3%

Price Change 3M -10.8%

Price Change 6M 9.8%

Price Change YTD 2.4%

Price Change 1Y -1.8%

Price Change 3Y 26.6%

Price Change 5Y 51.5%

1M CAGR (ann.) -11.9%

1Y CAGR (ann.) -1.2%

5Y CAGR (ann.) 8.3%

All-Time CAGR 13.7%

Valuation

PE Ratio 21.11

Forward PE 15.38

PEG Ratio 0.20

Forward PEG 0.53

PS Ratio 4.29

Forward PS 3.20

PB Ratio 3.63

P/FCF Ratio 16.63

P/Adj. FCF Ratio 22.76

P/OCF Ratio 16.19

EV/Sales 4.29

EV/EBIT 18.90

EV/EBITDA 15.40

EV/FCF 16.64

Earnings Yield 4.7%

FCF Yield 6.0%

Adj. FCF Yield 4.4%

Financial Health

Net Debt $12M

Total Debt $401.8M

Cash & Short-Term Investments $389.8M

Total Assets $5.36B

Current Ratio 1.87

Quick Ratio 1.75

Debt / Equity Ratio 0.11

Debt / EBITDA 0.43

Debt / FCF 0.46

OCF / Debt 2.24

Interest Coverage 272.03

Altman Z-Score 7.81

Piotroski F-Score 4

Margins & Profitability

Gross Profit Margin 98.0%

Operating Profit Margin 23.3%

EBITDA Margin 27.2%

Net Profit Margin 20.9%

FCF Margin 25.8%

Adj. FCF Margin 18.9%

SBC / Revenue 7.0%

SBC Impact (per share) -26.9%

Returns

Return on Assets 13.2%

Return on Equity 21.1%

Return on Invested Capital 13.2%

Return on Capital Employed 17.6%

Return on Tangible Assets 26.8%

Historical Growth (CAGR)

Revenue CAGR 3Y 26.3%

Revenue CAGR 5Y 26.7%

Revenue CAGR 10Y 71.9%

EPS CAGR 3Y 58.0%

EPS CAGR 5Y 12.9%

EPS CAGR 10Y 41.0%

FCF CAGR 3Y 45.8%

FCF CAGR 5Y 28.8%

FCF CAGR 10Y 33.5%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 37

EPS Growth Next 3Y 23.3%

Revenue Growth Next 3Y 16.3%

Earnings Date Oct 26, 2026

EPS Estimate (next Q) $2.59

EPS Growth Est (next Q) 27.0%

Revenue Est (next Q) $1.04B

Revenue Growth Est (next Q) 31.3%

Fair Value Estimates

Graham Number $74.91

Graham Upside -48.0%

Lynch Fair Value $87.91

Lynch Upside -38.9%

Price Target $203.82

Price Target Upside 41.6%

Cash Flow

Operating Cash Flow $898.1M

Free Cash Flow $870.4M

Adj. Free Cash Flow $635.9M

FCF Per Share $8.62

OCF Per Share $8.89

OCF/S Ratio 26.6%

Income Statement

Revenue $3.37B

Gross Profit $3.31B

Operating Income $787.4M

EBITDA $940.5M

Net Income $705.5M

EPS (Diluted) $6.82

Revenue / Employee $1.35M

Profit / Employee $282.2K

Employees 2,500